Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 1,697,942 |
|
|||||
| News | (1) | ||||||
| Day High | 7.40 | Low High |
|||||
| Day Low | 7.045 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Altimmune Inc | ALT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.09 | -1.22% | 7.27 | 17:13:59 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.40 | 7.045 | 7.40 | 7.27 | 7.36 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 14,716 | 1,697,942 | $ 7.24 | $ 12,300,985 | - | 2.09 - 14.84 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:21:37 | 11 | $ 7.29 | USD |
Altimmune Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 391.15M | 53.73M | - | 426k | -88.45M | -1.65 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Altimmune News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.35 | 7.63 | 6.31 | 7.04 | 2,719,965 | 0.92 | 14.49% |
| 1 Month | 8.60 | 8.71 | 6.282 | 7.31 | 2,953,707 | -1.33 | -15.47% |
| 3 Months | 9.86 | 14.84 | 6.282 | 9.73 | 4,618,611 | -2.59 | -26.27% |
| 6 Months | 2.76 | 14.84 | 2.315 | 8.00 | 7,934,796 | 4.51 | 163.41% |
| 1 Year | 4.95 | 14.84 | 2.09 | 7.26 | 4,663,880 | 2.32 | 46.87% |
| 3 Years | 12.98 | 23.49 | 2.09 | 8.85 | 2,577,327 | -5.71 | -43.99% |
| 5 Years | 2.99 | 35.10 | 1.45 | 10.03 | 2,153,820 | 4.28 | 143.14% |
Altimmune Description
| Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). |
